The Relative Strength (RS) Rating for Harmony Biosciences climbed into a new percentile Tuesday, as it got a lift from 69 to 78.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves. See if Harmony Biosciences can continue to show renewed price strength and clear that threshold.
Harmony Biosciences is trying to complete a consolidation with a 41.61 entry. See if it can clear the breakout price in volume at least 40% higher than normal.
Harmony Biosciences showed 17% EPS growth in the latest quarterly report, while sales growth came in at 19%.
The company holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
